Physician profile
Jamie E Brown
NPI 1770074783
$2,878.55
in general payments reported to CMS, 2019-2025
17 companies · $947 in 2025
The $947 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,215 · 2023: $264 · 2024: $452 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mid-Atlantic Surgical Systems, LLC | $1,215.30 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $384.12 | 2023-2025 | Lifevest |
| Stryker Corporation | $253.58 | 2025 | Artix Mt, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $147.17 | 2024-2025 | Avvigo Guidance System, Watchman |
| E.R. Squibb & Sons, L.L.C. | $145.19 | 2023-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $130.47 | 2023-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $122.92 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $86.71 | 2023-2025 | Farxiga |
| Amgen INC. | $84.07 | 2025 | Repatha |
| Heartflow, INC. | $83.71 | 2025 | |
| Abbott Laboratories | $71.77 | 2023-2025 | Cardiomems, Confirm Rx |
| Kiniksa Pharmaceuticals, LTD. | $43.38 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $33.56 | 2023 | Optimizer |
| Cvrx, INC. | $21.04 | 2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $20.88 | 2025 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $20.67 | 2025 | Flexitouch Plus, Nimbl |
| Novo Nordisk INC | $14.01 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.